

Henning Jann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9141886/henning-jann-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

904
citations

10
h-index

30
g-index

36
ext. papers

1,138
ext. citations

5.4
avg, IF

3.69
L-index

#	Paper	IF	Citations
32	Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	0
31	Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. <i>Cancers</i> , 2022 , 14, 2718	6.6	
30	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021 , 111, 217-236	5.6	4
29	Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial. <i>BMC Cancer</i> , 2021 , 21, 1206	4.8	0
28	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , 2021 , 14, 20	1.6	1
27	Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs. <i>Acta Radiologica</i> , 2021 , 62, 1006-1015	2	0
26	Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). <i>Cancers</i> , 2021 , 13,	6.6	6
25	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. <i>Cancers</i> , 2021 , 13,	6.6	3
24	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
23	PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. <i>Medicine (United States)</i> , 2021 , 100, e23835	1.8	3
22	A case report of an excellent response to interferon- β in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , 2020 , 99, e20820	1.8	0
21	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
20	Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis. <i>Visceral Medicine</i> , 2020 , 36, 20-27	2.4	1
19	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , 2020 , 15, e0244504	3.7	2
18	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1348-1355	3.1	26
17	Evaluating hepatotoxic effects of chemotherapeutic agents with gadoteric-acid-enhanced magnetic resonance imaging. <i>European Journal of Radiology</i> , 2020 , 124, 108807	4.7	2
16	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. <i>Diagnostics</i> , 2020 , 10,	3.8	3

15	Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2020 , 49, 912-917	2.6	4
14	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
13	Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 881-894	8.8	16
12	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , 2020 , 12,	6.6	10
11	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	54
10	Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 315-323	5.6	8
9	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 375-386	5.6	52
8	Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. <i>Neuroendocrinology</i> , 2017 , 104, 11-25	5.6	59
7	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. <i>Neuroendocrinology</i> , 2017 , 104, 170-182	5.6	63
6	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?. <i>Lancet Oncology, The</i> , 2017 , 18, e299	21.7	4
5	Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia. <i>Neuroendocrinology</i> , 2017 , 104, 135-144	5.6	2
4	Management of follow-up of neuroendocrine neoplasias. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016 , 30, 129-40	6.5	6
3	Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. <i>Endocrine-Related Cancer</i> , 2013 , 20, 305-19	5.7	26
2	Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. <i>Cancer</i> , 2011 , 117, 3332-41	6.4	204
1	Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. <i>Cancer</i> , 2008 , 113, 256-65	6.4	335